Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Non-Proliferative Diabetic Retinopathy Market Report 2024

Non-Proliferative Diabetic Retinopathy Global Market Report 2024 – By Treatment Type (Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Disease Severity Level (Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy), By End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

Non-Proliferative Diabetic Retinopathy Global Market Report 2024

Starting Price : $5000.00 | Pages : 175 | Published : June 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
Customise Your Report
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Non-Proliferative Diabetic Retinopathy Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Non-Proliferative Diabetic Retinopathy Market Definition And Segments

Non-proliferative diabetic retinopathy (NPDR) is a common complication of diabetes mellitus that affects the retina, the light-sensitive tissue lining the back of the eye. NPDR is characterized by changes in the blood vessels of the retina due to prolonged exposure to high levels of blood sugar (hyperglycemia) associated with diabetes. It is managed through a combination of medical interventions, lifestyle modifications, and regular eye examinations to prevent disease progression and preserve vision.

The main types of treatment for non-proliferative diabetic retinopathy include anti-vascular endothelial growth factor (VEGF) therapy, intraocular steroid injection, laser surgery, and vitrectomy. Anti-vascular endothelial growth factor (VEGF) therapy involves the use of medications that inhibit vascular endothelial growth factor (VEGF) to prevent abnormal blood vessel growth in the retina. This treatment is given for different severity levels include mild non-proliferative diabetic retinopathy, moderate non-proliferative diabetic retinopathy, and severe non-proliferative diabetic retinopathy in hospitals, specialty clinics, ambulatory surgical centers, and others.

The non-proliferative diabetic retinopathy market covered in this report is segmented –

1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy

2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy

3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users

The non-proliferative diabetic retinopathy market size has grown strongly in recent years. It will grow from $2.43 billion in 2023 to $2.62 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased prevalence of diabetes, aging population, improved awareness, research advancements, lifestyle changes and improved diabetes management.

The non-proliferative diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $3.58 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to adoption of telemedicine, development of novel therapeutics, integration of artificial intelligence, increasing investments in research and development, and expansion of healthcare infrastructure. Major trends in the forecast period include increasing adoption of artificial intelligence for screening and diagnosis, rising demand for telemedicine and remote monitoring solutions, emergence of, personalized medicine approaches for diabetic retinopathy treatment, growing focus on preventive strategies and early intervention, and expanding role of patient-centered care models in managing diabetic retinopathy.

Surging Prevalence Of Diabetes Fuels Growth In The Non-Proliferative Diabetic Retinopathy Market

The increasing prevalence of diabetes is expected to propel the growth of the non-proliferative diabetic retinopathy market going forward. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose (blood sugar) due to inadequate production of insulin by the pancreas or the body's cells becoming resistant to the effects of insulin. Diabetes is caused due to sedentary lifestyles, unhealthy dietary habits, and genetic predispositions. Diabetes induces non-proliferative diabetic retinopathy by damaging the blood vessels in the retina, primarily due to prolonged exposure to high levels of glucose in the bloodstream, resulting in vision impairment and potential blindness. For instance, in November 2021, according to the International Diabetes Federation, a Belgium-based umbrella organization of diabetes associations, approximately 537 million adults (20–79 years old) were living with diabetes in 2021. In contrast, the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the increasing prevalence of diabetes is driving the growth of the non-proliferative diabetic retinopathy market.

Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd.

Advancements In AI-Enabled Fundus Cameras For Non-Proliferative Diabetic Retinopathy

Major companies operating in the non-proliferative diabetic retinopathy market are developing AI-enabled cameras to improve patient outcomes and advance the field of ophthalmic imaging. AI-enabled cameras in ophthalmic imaging refer to devices equipped with artificial intelligence (AI) algorithms that assist in capturing, analyzing, and interpreting eye images for diagnostic and therapeutic purposes. For instance, in May 2024, Optomed, a Finland-based medical technology company, launched Optomed Aurora AEYE, a handheld AI fundus camera designed to detect more than mild diabetic retinopathy instantly. This innovative device combines the portability of a handheld camera with the power of artificial intelligence to provide high-quality retinal images for early detection and monitoring of various eye conditions. The Optomed Aurora AEYE utilizes AI algorithms to assist healthcare professionals in analyzing retinal images. This enables quick and accurate diagnosis of conditions such as diabetic retinopathy, glaucoma, and age-related macular degeneration.

Meteda Enhances Healthcare Offerings with Acquisition of Retmarker SA

In January 2022, Meteda S.r.l., an Italy-based nutrition solutions company, acquired Retmarker SA for an undisclosed amount. With this acquisition, Meteda has bolstered its capabilities in providing innovative and technologically advanced solutions for chronic diseases like diabetes, particularly in diabetic retinopathy screening, thereby expanding its potential to address the healthcare needs of a broader population and prevent blindness among individuals with diabetes worldwide. Retmarker SA is a Portugal-based biotechnology company that develops medical devices that serve as a biomarker for the progression of diabetic retinopathy.

North America was the largest region in the non-proliferative diabetic retinopathy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-proliferative diabetic retinopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-proliferative diabetic retinopathy (NPDR) market consists of revenues earned by entities by providing services such as ophthalmological consultations, optometric services, contract research services, and counselling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-proliferative diabetic retinopathy (NPDR) market also includes sales of fundus cameras, optical coherence tomography (OCT) machines, laser photocoagulation equipment, and injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The non-proliferative diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides non-proliferative diabetic retinopathy market statistics, including non-proliferative diabetic retinopathy industry global market size, regional shares, competitors with a non-proliferative diabetic retinopathy market share, detailed non-proliferative diabetic retinopathy market segments, market trends and opportunities, and any further data you may need to thrive in the non-proliferative diabetic retinopathy industry. This non-proliferative diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-Proliferative Diabetic Retinopathy Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $2.62 billion
Revenue Forecast In 2033 $3.58 billion
Growth Rate CAGR of 8.1% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Non-Proliferative Diabetic Retinopathy Market Characteristics

    3. Non-Proliferative Diabetic Retinopathy Market Trends And Strategies

    4. Non-Proliferative Diabetic Retinopathy Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Non-Proliferative Diabetic Retinopathy Market Size and Growth

    5.1. Global Non-Proliferative Diabetic Retinopathy Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Non-Proliferative Diabetic Retinopathy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Non-Proliferative Diabetic Retinopathy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Non-Proliferative Diabetic Retinopathy Market Segmentation

    6.1. Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Anti-Vascular Endothelial Growth Factor (VEGF) Therapy

    Intraocular Steroid Injection

    Laser Surgery

    Vitrectomy

    6.2. Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Mild Non-Proliferative Diabetic Retinopathy

    Moderate Non-Proliferative Diabetic Retinopathy

    Severe Non-Proliferative Diabetic Retinopathy

    6.3. Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Specialty Clinics

    Ambulatory Surgical Centers

    Other End-Users

    7. Non-Proliferative Diabetic Retinopathy Market Regional And Country Analysis

    7.1. Global Non-Proliferative Diabetic Retinopathy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Non-Proliferative Diabetic Retinopathy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market

    8.1. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Non-Proliferative Diabetic Retinopathy Market

    9.1. China Non-Proliferative Diabetic Retinopathy Market Overview

    9.2. China Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Non-Proliferative Diabetic Retinopathy Market

    10.1. India Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Non-Proliferative Diabetic Retinopathy Market

    11.1. Japan Non-Proliferative Diabetic Retinopathy Market Overview

    11.2. Japan Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Non-Proliferative Diabetic Retinopathy Market

    12.1. Australia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Non-Proliferative Diabetic Retinopathy Market

    13.1. Indonesia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Non-Proliferative Diabetic Retinopathy Market

    14.1. South Korea Non-Proliferative Diabetic Retinopathy Market Overview

    14.2. South Korea Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Non-Proliferative Diabetic Retinopathy Market

    15.1. Western Europe Non-Proliferative Diabetic Retinopathy Market Overview

    15.2. Western Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Non-Proliferative Diabetic Retinopathy Market

    16.1. UK Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Non-Proliferative Diabetic Retinopathy Market

    17.1. Germany Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Non-Proliferative Diabetic Retinopathy Market

    18.1. France Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Non-Proliferative Diabetic Retinopathy Market

    19.1. Italy Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Non-Proliferative Diabetic Retinopathy Market

    20.1. Spain Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Non-Proliferative Diabetic Retinopathy Market

    21.1. Eastern Europe Non-Proliferative Diabetic Retinopathy Market Overview

    21.2. Eastern Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Non-Proliferative Diabetic Retinopathy Market

    22.1. Russia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Non-Proliferative Diabetic Retinopathy Market

    23.1. North America Non-Proliferative Diabetic Retinopathy Market Overview

    23.2. North America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Non-Proliferative Diabetic Retinopathy Market

    24.1. USA Non-Proliferative Diabetic Retinopathy Market Overview

    24.2. USA Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Non-Proliferative Diabetic Retinopathy Market

    25.1. Canada Non-Proliferative Diabetic Retinopathy Market Overview

    25.2. Canada Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Non-Proliferative Diabetic Retinopathy Market

    26.1. South America Non-Proliferative Diabetic Retinopathy Market Overview

    26.2. South America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Non-Proliferative Diabetic Retinopathy Market

    27.1. Brazil Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Non-Proliferative Diabetic Retinopathy Market

    28.1. Middle East Non-Proliferative Diabetic Retinopathy Market Overview

    28.2. Middle East Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Non-Proliferative Diabetic Retinopathy Market

    29.1. Africa Non-Proliferative Diabetic Retinopathy Market Overview

    29.2. Africa Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Non-Proliferative Diabetic Retinopathy Market Competitive Landscape And Company Profiles

    30.1. Non-Proliferative Diabetic Retinopathy Market Competitive Landscape

    30.2. Non-Proliferative Diabetic Retinopathy Market Company Profiles

    30.2.1. Pfizer Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Johnson & Johnson

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. F. Hoffmann-La Roche AG

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. AbbVie Inc.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Bayer AG

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Non-Proliferative Diabetic Retinopathy Market Other Major And Innovative Companies

    31.1. Abbott Laboratories

    31.2. Novartis AG

    31.3. Eli Lilly and Company

    31.4. Novo Nordisk A/S

    31.5. Regeneron Pharmaceuticals Inc.

    31.6. Bausch Health Companies Inc.

    31.7. Boehringer Ingelheim International GmbH

    31.8. Genentech Inc.

    31.9. Carl Zeiss Meditec AG

    31.10. ZEISS Group

    31.11. Santen Pharmaceutical Co. Ltd.

    31.12. Santen Inc.

    31.13. Topcon Corporation

    31.14. Lumenis Ltd.

    31.15. Alimera Science

    32. Global Non-Proliferative Diabetic Retinopathy Market Competitive Benchmarking

    33. Global Non-Proliferative Diabetic Retinopathy Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Non-Proliferative Diabetic Retinopathy Market

    35. Non-Proliferative Diabetic Retinopathy Market Future Outlook and Potential Analysis

    35.1 Non-Proliferative Diabetic Retinopathy Market In 2028 - Countries Offering Most New Opportunities

    35.2 Non-Proliferative Diabetic Retinopathy Market In 2028 - Segments Offering Most New Opportunities

    35.3 Non-Proliferative Diabetic Retinopathy Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Non-Proliferative Diabetic Retinopathy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Non-Proliferative Diabetic Retinopathy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Pfizer Inc. Financial Performance
  • Table 75: Johnson & Johnson Financial Performance
  • Table 76: F. Hoffmann-La Roche AG Financial Performance
  • Table 77: AbbVie Inc. Financial Performance
  • Table 78: Bayer AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Non-Proliferative Diabetic Retinopathy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Non-Proliferative Diabetic Retinopathy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Pfizer Inc. Financial Performance
  • Figure 75: Johnson & Johnson Financial Performance
  • Figure 76: F. Hoffmann-La Roche AG Financial Performance
  • Figure 77: AbbVie Inc. Financial Performance
  • Figure 78: Bayer AG Financial Performance
Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis
Read More
How Will The Nuclear Medicine Market Grow In 2022?
Read More
What Is The Pediatric Imaging Market Overview In 2022?
Read More
Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth
Read More
Diabetic Foot Ulcer Global Market Report 2024 – By Type (Advanced Wound Care Dressings, Biologics, Therapy Device), By Ulcer Type (Neuropathic Ulcers, Ischemic Ulcers, Neuro-ischemic Ulcers), By End-User (Hospitals, Ambulatory Surgery Centers, Home Care) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Proliferative Diabetic Retinopathy (PDR) Global Market Report 2024 – By Treatment Type (Anti-VEGF (Vascular Endothelial Growth Factor) Therapy, Intraocular Steroids, Laser Surgery, Vitrectomy), By Mode of Administration (Injectables, Oral, Other Mode Of Administrations), By Application (Hospitals, Clinics, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Diabetic Gastroparesis Treatment Global Market Report 2024 – By Treatment (Medication, Surgery), By Route Of Administration (Oral, Injectables), By Indication (Compensated Gastroparesis, Gastric Failure), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Diabetic Retinopathy Global Market Report 2024 – By Type (Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy), By Treatment (Anti-VEGF Drugs, Intraocular Steroid Injection, Laser Photocoagulation, Vitreoretinal Surgery), By End-User (Hospitals, Ambulatory Surgical Centers, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Diabetic Kidney Disease Global Market Report 2024 – By Type (Type 1 Diabetes, Type 2 Diabetes), By Treatment (Angiotensin Receptor Blockers (Arbs), Angiotensin-Converting Enzyme (Ace) Inhibitors, Antioxidant Inflammation Modulator, Calcium Channel Blockers, Other Treatments), By End User (Hospitals, Homecare, Specialty Centers, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Diabetic Neuropathy Global Market Report 2024 – By Disorder (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), By Drug Class (Analgesics, Anti-Depressants, Anti-convulsant, Other Drug Classes), By Treatment (Drug Treatment, Radiotherapy, Physiotherapy, Other Treatments), By Distribution Channel (Online Distribution, Offline Distribution), By End-user (Hospitals, Specialty Clinics, Other End-users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Diabetic Foot Ulcer Treatment Global Market Report 2024 – By Treatment( Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications, Other Treatments), By Ulcer Type( Neuropathic Ulcers, Ischemic Ulcers, Neuro-Ischemic Ulcers), By Grade( Grade 1, Grade 2, Grade 3, Grade 4, Grade 5), By End-User( Hospital, Ambulatory Surgery Centre, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Diabetic Footwear Global Market Report 2024 – By Type (Shoes, Sandals, Slippers), By Distribution Channel (Online Platform, Specialty Stores, Footwear Stores, Other Distribution Channels), By End User (Men, Women) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the non-proliferative diabetic retinopathy market?

Non-proliferative diabetic retinopathy (NPDR) is a common complication of diabetes mellitus that affects the retina, the light-sensitive tissue lining the back of the eye. NPDR is characterized by changes in the blood vessels of the retina due to prolonged exposure to high levels of blood sugar (hyperglycemia) associated with diabetes. It is managed through a combination of medical interventions, lifestyle modifications, and regular eye examinations to prevent disease progression and preserve vision. For further insights on the non-proliferative diabetic retinopathy market, request a sample here

How will the non-proliferative diabetic retinopathy market drivers and restraints affect the non-proliferative diabetic retinopathy market dynamics? What forces will shape the non-proliferative diabetic retinopathy industry going forward?

The non-proliferative diabetic retinopathy market major growth driver - Surging Prevalence Of Diabetes Fuels Growth In The Non-Proliferative Diabetic Retinopathy Market. For further insights on the non-proliferative diabetic retinopathy market, request a sample here

What is the forecast market size or the forecast market value of the non-proliferative diabetic retinopathy market?

The non-proliferative diabetic retinopathy market size has grown strongly in recent years. It will grow from $2.43 billion in 2023 to $2.62 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased prevalence of diabetes, aging population, improved awareness, research advancements, lifestyle changes and improved diabetes management. The non-proliferative diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $3.58 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to adoption of telemedicine, development of novel therapeutics, integration of artificial intelligence, increasing investments in research and development, and expansion of healthcare infrastructure. Major trends in the forecast period include increasing adoption of artificial intelligence for screening and diagnosis, rising demand for telemedicine and remote monitoring solutions, emergence of, personalized medicine approaches for diabetic retinopathy treatment, growing focus on preventive strategies and early intervention, and expanding role of patient-centered care models in managing diabetic retinopathy. For further insights on the non-proliferative diabetic retinopathy market, request a sample here

How is the non-proliferative diabetic retinopathy market segmented?

The non-proliferative diabetic retinopathy market is segmented
1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-UsersFor further insights on the non-proliferative diabetic retinopathy market, request a sample here

Which region has the largest share of the non-proliferative diabetic retinopathy market? What are the other regions covered in the report?

North America was the largest region in the non-proliferative diabetic retinopathy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the non-proliferative diabetic retinopathy market, request a sample here.

Who are the major players in the non-proliferative diabetic retinopathy market?

Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc. , Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd. For further insights on the non-proliferative diabetic retinopathy market, request a sample here.

What are the key trends in the non-proliferative diabetic retinopathy market?

Major trend in the non-proliferative diabetic retinopathy market - Advancements In AI-Enabled Fundus Cameras For Non-Proliferative Diabetic Retinopathy. For further insights on the non-proliferative diabetic retinopathy market, request a sample here.

What are the major opportunities in the non-proliferative diabetic retinopathy market? What are the strategies for the non-proliferative diabetic retinopathy market?

For detailed insights on the major opportunities and strategies in the non-proliferative diabetic retinopathy market, request a sample here.

How does the non-proliferative diabetic retinopathy market relate to the overall economy and other similar markets?

For detailed insights on non-proliferative diabetic retinopathy market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the non-proliferative diabetic retinopathy industry?

For detailed insights on the mergers and acquisitions in the non-proliferative diabetic retinopathy industry, request a sample here.

What are the key dynamics influencing the non-proliferative diabetic retinopathy market growth? SWOT analysis of the non-proliferative diabetic retinopathy market.

For detailed insights on the key dynamics influencing the non-proliferative diabetic retinopathy market growth and SWOT analysis of the non-proliferative diabetic retinopathy industry, request a sample here.